John Libbey Eurotext

European Journal of Dermatology


Effects of risankizumab in patients with psoriasis previously treated with guselkumab: a case series Volume 31, numéro 2, March-April 2021


1 Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan
2 Department of Dermatology, National Taiwan University College of Medicine, Taipei, Taiwan

The development of biologics has revolutionized the treatment of psoriasis, and biologics targeting interleukin-23 (IL-23), including guselkumab and risankizumab, represent the most recent generation of treatment [1]. We are seeing a higher proportion of patients switching to biologics in clinical trials [2]. Despite the presence of many head-to-head studies, pivotal studies usually exclude patients exposed to the same class of biologic. However, switching within the same class is common in real-world [...]